Drug Trial Radar · NCT07734116
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Nov 30, 2029
Study completion Feb 29, 2032
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma, and to evaluate the tolerability in pediatric patients. The objective of this study is to explore the tolerability, safety, efficacy, and pharmacokinetics of ONO-4538HSC in patients with pediatric malignant solid tumors. The other objective is to exploratively investigate the efficacy and safety of ONO-4538HSC in patients with epithelioid sarcoma.
Conditions
- Pediatric Malignant Solid Tumor and Epithelioid Sarcoma
Interventions
ONO-4538HSCDrug
ONO-4538HSC will be administered subcutaneously once every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events meeting protocol-defined criteria for a DLTTime frame: 28 days
- Serious adverse eventsTime frame: UP to 100 days after the last dose
- Adverse eventsTime frame: UP to 100 days after the last dose
- Response rate (central assessment)Time frame: Through study completion, an average of 6 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Chiba University Hospital
Chiba, Chiba, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Not yet recruiting
Kyushu University Hospital
Fukuoka, Fukuoka, Japan · Recruiting
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan · Not yet recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan · Not yet recruiting
Yokohama City University Hospital
Yokohama, Kanagawa, Japan · Not yet recruiting
Kyoto University Hospital
Kyoto, Kyoto, Japan · Recruiting
Mie University Hospital
Tsu, Mie-ken, Japan · Not yet recruiting
Tohoku University Hospital
Sendai, Miyagi, Japan · Not yet recruiting
Okayama University Hospital
Okayama, Okayama-ken, Japan · Not yet recruiting
Osaka International Cancer Institute
Osaka, Osaka, Japan · Recruiting
Kindai University Hospital
Sakai, Osaka, Japan · Not yet recruiting
Shizuoka Cancer Center
Sunto-gun, Shizuoka, Japan · Not yet recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.